fbpx

Spine | Intervention

Brochure

Leader Biomedical’s Spine Intervention portfolio offers targeted solutions for treating osteoarthritis, spinal fusion, and adhesion control and prevention.

Please send this document to my inbox

Fields marked with * are required
LB – spine-woman stretching from back

Hyalosyn™ Gel

Hyalosyn™ Gel is a 1% sodium hyaluronate viscoelastic solution in a sterile, pre-filled syringe for improved joint mobility with three to five injections (one per week). Hyalosyn™ Gel increases the shock-absorbing capacity of joints and relieves joint pain caused by osteoarthristis, or at first signs of movement limitations and joint pain.

  • Manufactured by synthetic fermentation
  • No microbiological residues
  • Suitable for intra-articular injection into all synovial joints
  • Sterile pre-filled syringe for easy injection
  • Clinically proven therapy for osteoarthritis for more than 10 years

Adcon® Gel - adhesion control barrier gel

Adcon® Gel is a biocompatible resorbable gel, composed of polyglycan ester combined with absorbable gelatine in a phosphate-buffered saline. Adcon® Gel provides a physical barrier to inter-tissue adhesions and inhibits fibroblast migration and ingrowth. This results in improved patient rehabilitation, reduced recurrent pain, and decreased number of re-operations as a result of such adhesions. The design of Adcon® Gel establishes a temporary basal lamina by combining an absorbable, collagen-derived material with a resorbable polyglycan ester.

  • Prevents adhesion formation
  • Resorbable
  • Extensive clinical history
  • Ease of use

eTiss® allografts

All Leader Biomedical allografts are processed with our proprietary eCOO® Technology, a mild and efficient platform using supercritical carbon dioxide (scCO2) to clean, sterilise, and impregnate human and animal-derived bone and tissue with limited use of chemicals. For spine intervention treatments, we offer eTiss® cancellous and cortical bone chips with sound structural and mechanical properties for filling of bone loss and/or correcting of defects as well as eTiss® DBM cortical bone demineralised with the goal of exposing encapsulated growth factors, such as bone morphogenetic proteins (BMPs).

Properties of eCOO® allografts

  • Macroporous: stimulating cell colonisation and osteoconduction
  • Microporous: enabling biologic fluids to pass through the construct
  • Bioactive: ensuring the tissue graft interacts with the patient’s body

OssGro® synthetic bone grafts

Leader Biomedical’s OssGro® synthetic bone grafts are produced with MBCP Technology, a proprietary method for producing high quality synthetic bone grafts composed of 60% HA and 40% βTCP. For spine intervention treatments, our portfolio offers OssGro® granules (in vial or syringe) and wedges to support new bone formation promoted by the release of calcium and phosphate ions as well as Ossfinity® putty that combines OssGro® granules and an absorbable hydrogel to create a putty, which acts as a carrier for rapid vascularisation and mineralisation.

The MBCP™ advantage:

  • Regeneration
  • Porosity (macro and micro)
  • Permeability
  • Safety
  • Availability

Please send this document to my inbox

Fields marked with * are required